View Older Stories View More Recent Stories

Jul 28, 2025 09:25AM Lexaria reports reduced side effects in GLP-1 drug trial
Jul 28, 2025 09:25AM Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study
Jul 23, 2025 09:28AM Lexaria claims technology could reduce GLP-1 drug side effects
Jul 23, 2025 09:25AM Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry
Jul 1, 2025 06:42AM Lexaria Bioscience (LEXX) PT Lowered to $5 at H.C. Wainwright
Jun 23, 2025 09:15AM Lexaria Bioscience (LEXX) Reaches Patent Milestone - 50 Patents Now Granted Worldwide
Jun 23, 2025 09:15AM Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide
Jun 13, 2025 04:10PM Lexaria Bioscience (LEXX) Files for 41.63M Share Offering by Selling Stockholders
Jun 11, 2025 09:05AM Lexaria's (LEXX) DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule
Jun 11, 2025 09:05AM Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule
Jun 5, 2025 09:20AM Lexaria Attending BIO International Convention
May 12, 2025 09:02AM Lexaria Bioscience (LEXX) Provides Update on Material Transfer Agreement with Pharmaceutical Company
May 12, 2025 09:00AM Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company
Apr 28, 2025 04:15PM Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock
Apr 25, 2025 08:02AM Lexaria Bioscience (LEXX) Prices 2M Share Offering at $1/sh
Apr 25, 2025 08:00AM Lexaria Announces $2 Million Registered Direct Offering of Common Stock
Apr 23, 2025 09:10AM Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology
Apr 3, 2025 09:14AM Lexaria Bioscience (LEXX) Updates its Ongoing Human Study GLP-1-H24-4
Apr 3, 2025 09:10AM Lexaria Updates its Ongoing Human Study GLP-1-H24-4
Apr 2, 2025 09:13AM Lexaria Bioscience (LEXX) announces human dosing in GLP-1 study
Apr 2, 2025 09:05AM Lexaria's Human GLP-1 Study #5 Begins Dosing
Mar 18, 2025 09:16AM Lexaria Bioscience's (LEXX) DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound
Mar 18, 2025 09:15AM Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R)
Feb 27, 2025 08:00AM The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience
Feb 24, 2025 08:02AM Lexaria Bioscience (LEXX) Reports Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm
Feb 24, 2025 08:00AM Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm
Feb 20, 2025 08:04AM Lexaria Bioscience (LEXX) Strategic Business Pursuit of DehydraTECH-Liraglutide
Feb 20, 2025 08:00AM Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide
Feb 11, 2025 08:03AM Lexaria Bioscience (LEXX) Granted Two New DehydraTECH Patents for Treatment of Epilepsy
Feb 11, 2025 08:00AM Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy
Feb 6, 2025 09:42AM Lexaria Bioscience (LEXX) Biodistribution Study For DehydraTECH GLP-1 is Underway
Feb 6, 2025 09:40AM Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway
Feb 5, 2025 09:14AM Lexaria Bioscience (LEXX) Updates its Ongoing Human Study GLP-1-H24-4
Feb 5, 2025 09:10AM Lexaria Updates its Ongoing Human Study GLP-1-H24-4
Jan 30, 2025 09:17AM Lexaria Bioscience (LEXX) Releases Annual Letter from the CEO
Jan 30, 2025 09:15AM Lexaria Releases Annual Letter from the CEO
Jan 24, 2025 06:39AM Lexaria Bioscience (LEXX) PT Lowered to $7 at H.C. Wainwright
Jan 22, 2025 04:09PM Lexaria Bioscience (LEXX) Files $50M Mixed Shelf
Jan 15, 2025 09:28AM Lexaria Bioscience's (LEXX) Human GLP-1 Study #5 Receives Independent Review Board Approval
Jan 15, 2025 09:20AM Lexaria’s Human GLP-1 Study #5 Receives Independent Review Board Approval
Jan 14, 2025 09:12AM Lexaria Bioscience's (LEXX) Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound
Jan 14, 2025 09:10AM Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)
Dec 23, 2024 07:10AM H.C. Wainwright Reiterates Buy Rating on Lexaria Bioscience (LEXX)
Dec 19, 2024 09:05AM Lexaria's Registered GLP-1 Study #4 Begins Dosing
Dec 18, 2024 09:26AM Lexaria Bioscience (LEXX) Forms New Scientific Advisory Board
Dec 18, 2024 09:25AM Lexaria Forms New Scientific Advisory Board
Dec 17, 2024 09:11AM Lexaria Bioscience (LEXX) Appoints Michael Gibson as Chief Medical Advisor
Dec 17, 2024 09:10AM Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience
Dec 9, 2024 09:10AM Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5
Dec 2, 2024 06:48AM H.C. Wainwright Reiterates Buy Rating on Lexaria Bioscience (LEXX)
View More Recent Stories View Older Stories